Study allays fears over long-term alendronate

LONG-TERM users of the osteoporosis drug alendronate are at no greater risk of developing atypical femur fractures over at least 10 years of treatment, a Danish study shows.

The finding comes as fears of bisphosphonate side effects kindled in the mainstream media are leading many osteoporosis patients to abandon their treatment.

Researchers found the